NO20004218L - Increasing the circulating half-life of an antibody-based fusion protein - Google Patents

Increasing the circulating half-life of an antibody-based fusion protein

Info

Publication number
NO20004218L
NO20004218L NO20004218A NO20004218A NO20004218L NO 20004218 L NO20004218 L NO 20004218L NO 20004218 A NO20004218 A NO 20004218A NO 20004218 A NO20004218 A NO 20004218A NO 20004218 L NO20004218 L NO 20004218L
Authority
NO
Norway
Prior art keywords
antibody
life
increasing
fusion protein
circulating half
Prior art date
Application number
NO20004218A
Other languages
Norwegian (no)
Other versions
NO20004218D0 (en
Inventor
Stephen D Gillies
Kin-Ming Lo
Yan Lan
John Wesolowski
Original Assignee
Lexigen Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharm Corp filed Critical Lexigen Pharm Corp
Publication of NO20004218D0 publication Critical patent/NO20004218D0/en
Publication of NO20004218L publication Critical patent/NO20004218L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20004218A 1998-02-25 2000-08-23 Increasing the circulating half-life of an antibody-based fusion protein NO20004218L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7588798P 1998-02-25 1998-02-25
PCT/US1999/003966 WO1999043713A1 (en) 1998-02-25 1999-02-24 Enhancing the circulating half-life of antibody-based fusion proteins

Publications (2)

Publication Number Publication Date
NO20004218D0 NO20004218D0 (en) 2000-08-23
NO20004218L true NO20004218L (en) 2000-10-24

Family

ID=22128576

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004218A NO20004218L (en) 1998-02-25 2000-08-23 Increasing the circulating half-life of an antibody-based fusion protein

Country Status (11)

Country Link
EP (1) EP1060194A1 (en)
JP (1) JP2002505086A (en)
CN (1) CN1204147C (en)
AU (1) AU758240B2 (en)
BR (1) BR9908226A (en)
CA (1) CA2320403A1 (en)
CZ (1) CZ20003099A3 (en)
HU (1) HUP0100813A3 (en)
NO (1) NO20004218L (en)
PL (1) PL199659B1 (en)
WO (1) WO1999043713A1 (en)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
ES2221717T3 (en) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. USEFUL HETERODIMERAS FUSION PROTEINS FOR DIRECTED IMMUNOTHERAPY AND GENERAL IMMUNOSTIMULATION.
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (en) 1999-01-15 2011-10-26 제넨테크, 인크. Polypeptide Variants with Altered Effector Function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6617135B1 (en) 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
GB9926084D0 (en) * 1999-11-03 2000-01-12 King S College London Recombinant fusion molecules
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
DK1252192T3 (en) 2000-02-11 2006-11-20 Merck Patent Gmbh Enhancement of the serum half-life of antibody-based fusion proteins
EP2264072A1 (en) 2000-04-13 2010-12-22 The Rockefeller University Enhancement of antibody-mediated cytotoxicity.
RU2272644C2 (en) 2000-06-29 2006-03-27 Мерк Патент Гмбх Enhancement of immune response wherein fused protein antibody-cytokine is mediator by combined treatment with agents increasing immunocytokine absorption
DE10045591A1 (en) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Site-specific, antibody-mediated activation of proapoptotic cytokines - AMAIZe (Antibody-Mediated Apoptosis Inducing Cytokines)
AU2011253690C1 (en) * 2000-12-12 2018-01-18 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
PT1355919E (en) * 2000-12-12 2011-03-02 Medimmune Llc Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR100900176B1 (en) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 Expression Techniques for Proteins Containing Hybrid Isotype Antibody Substructures
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CA2446087C (en) 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
BR0214650A (en) 2001-12-04 2005-05-03 Merck Patent Gmbh Modulated selectivity immunocytokines
WO2003089614A2 (en) * 2002-04-18 2003-10-30 Genencor International, Inc. Production of functional antibodies in filamentous fungi
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US7217798B2 (en) 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1562972T3 (en) * 2002-10-15 2010-12-06 Facet Biotech Corp Modification of FcRn binding affinities or serum half-lives for antibodies by mutagenesis
JP4494977B2 (en) 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Humanized antibody (H14.18) of mouse 14.18 antibody that binds to GD2 and its IL-2 fusion protein
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
PT1624891E (en) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Clotting factor-fc chimeric proteins to treat hemophilia
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP2005073528A (en) * 2003-08-28 2005-03-24 Genetics Inst Llc Method for inhibiting adhesion of blood to biological tissue in biological system, and composition for being used for the method
DK1699822T3 (en) 2003-12-30 2008-08-04 Merck Patent Gmbh IL-7 fusion proteins with antibody moieties, their preparation and their use
WO2005063808A1 (en) 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
EA011859B9 (en) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Compounds for targeted preparation delivery to tissue or targeted organ
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
ATE465176T1 (en) 2004-12-09 2010-05-15 Merck Patent Gmbh IL-7 VARIANTS WITH REDUCED IMMUNOGENITY
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2460517T3 (en) 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reduction of b cells by using cd37 specific binding and cd20 specific binding molecules
CA2618681C (en) 2005-08-10 2015-10-27 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
PT2029173T (en) 2006-06-26 2016-11-02 Macrogenics Inc Fc riib-specific antibodies and methods of use thereof
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
ATE480568T1 (en) * 2006-06-30 2010-09-15 Conaris Res Inst Ag IMPROVED SGP 130FC DIMERE
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
TW200907056A (en) * 2007-03-28 2009-02-16 Astrazeneca Ab New method
PE20140196A1 (en) 2007-08-09 2014-03-19 Boehringer Ingelheim Int ANTI-CD37 ANTIBODIES
MX2010005104A (en) 2007-11-09 2010-08-04 Peregrine Pharmaceuticals Inc Anti-vegf antibody compositions and methods.
US8795667B2 (en) 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
BRPI0907046A2 (en) 2008-01-18 2015-07-28 Medimmune Llc Engineered cysteine antibody, isolated nucleic acid, vector, host cell, antibody conjugate, pharmaceutical composition, methods of detecting cancer, autoimmune, inflammatory or infectious disorders in an individual and inhibiting proliferation of a target cell
PL2247304T3 (en) 2008-04-02 2017-01-31 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
US8669349B2 (en) 2008-04-02 2014-03-11 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
PT2132228E (en) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8775090B2 (en) 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
TWI440470B (en) * 2009-03-19 2014-06-11 Chugai Pharmaceutical Co Ltd Pharmaceutical formulation containing improved antibody molecules
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
US20120134984A1 (en) 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
WO2011005481A1 (en) 2009-06-22 2011-01-13 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
CN102666874B (en) 2009-10-07 2016-06-01 宏观基因有限公司 Polypeptide and the using method thereof in the effector function Han Fc district of improvement is shown due to the change of fucosylation degree
US8722615B2 (en) 2009-12-02 2014-05-13 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
TWI505838B (en) 2010-01-20 2015-11-01 中外製藥股份有限公司 Stabilized antibody
DK2542256T3 (en) 2010-03-04 2019-08-26 Macrogenics Inc ANTIBODIES REACTIVE WITH B7-H3, IMMUNOLOGICALLY ACTIVE FRAGMENTS THEREOF AND APPLICATIONS THEREOF
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CA2807127C (en) 2010-08-02 2019-02-12 Leslie S. Johnson Covalent diabodies and uses thereof
UA112062C2 (en) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх CD33-Binding Agent
WO2012069433A2 (en) 2010-11-23 2012-05-31 Glaxo Group Limited Antigen binding proteins
JP2014501725A (en) 2010-11-24 2014-01-23 グラクソ グループ リミテッド Multispecific antigen binding protein targeting HGF
JP6147670B2 (en) 2010-12-22 2017-06-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Modified antibodies with improved half-life
BR112013024574B1 (en) 2011-03-29 2022-08-09 Roche Glycart Ag ANTIBODY AND ANTIBODY USE
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
WO2012162068A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
CN103842380A (en) 2011-07-27 2014-06-04 葛兰素集团有限公司 Anti-VEGF single variable domains fused to Fc domains
DK2771022T3 (en) 2011-10-11 2020-09-28 Viela Bio Inc CD40L-SPECIFIC TN3-DERIVATED SKELETS (SCAFFOLDS) AND METHODS OF USING IT
JP2015502397A (en) 2011-12-23 2015-01-22 ファイザー・インク Engineered antibody constant regions for site-specific conjugation, and methods and uses therefor
EP2872534B1 (en) 2012-07-13 2018-08-08 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
RU2015106812A (en) * 2012-08-02 2016-09-27 Ф.Хоффманн-Ля Рош Аг METHOD FOR PRODUCING MONOMERIC AND MULTIMETERAL MOLECULES AND THEIR APPLICATION
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
TWI635098B (en) 2013-02-01 2018-09-11 再生元醫藥公司 Antibody containing chimeric constant region
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
EP2968520B1 (en) 2013-03-14 2021-05-12 MacroGenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
HRP20201113T1 (en) 2013-03-15 2020-10-30 Glaxosmithkline Intellectual Property Development Limited Anti-lag-3 binding proteins
UA116479C2 (en) 2013-08-09 2018-03-26 Макродженікс, Інк. SPECIFIC MONOVALENT Fc-DIATELY CONNECTING BACKGROUND OF THE CD32B AND CD79b AND ITS APPLICATION
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
CN111423513A (en) 2014-02-06 2020-07-17 豪夫迈·罗氏有限公司 Interleukin-2 fusion protein and use thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TWI701042B (en) 2014-03-19 2020-08-11 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
CN106413750B (en) 2014-05-16 2022-04-29 免疫医疗有限责任公司 Molecules with altered neonatal Fc receptor binding with enhanced therapeutic and diagnostic properties
HK1231496A1 (en) 2014-06-20 2017-12-22 豪夫迈．罗氏有限公司 Chagasin-based scaffold compositions, methods, and uses
SG11201700629TA (en) 2014-08-11 2017-02-27 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
US10717778B2 (en) 2014-09-29 2020-07-21 Duke University Bispecific molecules comprising an HIV-1 envelope targeting arm
AU2015350075B2 (en) 2014-11-17 2021-06-03 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using CD3xCD20 bispecific antibody
EP3263132B1 (en) 2015-02-27 2023-12-06 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
US10556952B2 (en) 2015-03-30 2020-02-11 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to Fc gamma receptors
GB201506389D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506393D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
WO2017019729A1 (en) 2015-07-27 2017-02-02 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
RU2021133819A (en) 2015-09-02 2021-12-10 Иммутеп С.A.С. ANTI-LAG-3 ANTIBODIES
TWI799366B (en) 2015-09-15 2023-04-21 美商建南德克公司 Cystine knot scaffold platform
MX2018003292A (en) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Cd3 binding polypeptides.
TWI784917B (en) 2015-09-23 2022-11-21 美商再生元醫藥公司 Optimized anti-cd3 bispecific antibodies and uses thereof
EP3383891A1 (en) 2015-12-04 2018-10-10 Novartis AG Antibody cytokine engrafted compositions and methods of use for immunoregulation
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
TWI781098B (en) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
TWI640536B (en) 2016-06-20 2018-11-11 克馬伯有限公司 antibody
WO2018049275A1 (en) 2016-09-09 2018-03-15 Genentech, Inc. Selective peptide inhibitors of frizzled
JP7213180B2 (en) * 2016-10-19 2023-01-26 エフ．ホフマン－ラ ロシュ アーゲー Methods for manufacturing immunoconjugates
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD FOR PREDICTING AND EVALUATING A THERAPEUTIC EFFECT IN DISEASES ASSOCIATED WITH IL-6 AND NEUTROPHILS
IL322309A (en) 2017-05-24 2025-09-01 Novartis Ag Antibody IL2 engrafted proteins and methods of use in the treatment of cancer”
JOP20190271A1 (en) 2017-05-24 2019-11-21 Novartis Ag Cytokine-Encapsulated Proteins - Antibody and Methods for Use for Immune-Related Disorders
AU2018347607B2 (en) 2017-10-14 2025-08-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
EP3728302A1 (en) 2017-12-19 2020-10-28 Xencor, Inc. Engineered il-2 fc fusion proteins
IL280875B2 (en) 2018-08-31 2024-12-01 Regeneron Pharma Cytokine release syndrome-attenuating dosing strategy for bispecific antibodies to CD3 and CD20
US12331119B2 (en) * 2019-02-22 2025-06-17 Wuhan Yzy Biopharma Co., Ltd. Modified Fc fragment, antibody comprising same, and application thereof
NZ784975A (en) 2019-08-06 2025-10-31 Glaxosmithkline Ip Dev Ltd Biopharmacuetical compositions and related methods
CN114867749A (en) * 2019-12-17 2022-08-05 安进公司 Dual interleukin-2/TNF receptor agonists for use in therapy
CN115697404A (en) 2020-05-29 2023-02-03 中外制药株式会社 Antibody-containing preparation
JP2024521187A (en) 2021-05-28 2024-05-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Combination Therapy for the Treatment of Cancer
TW202323822A (en) 2021-08-03 2023-06-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 Biopharmaceutical compositions and stable isotope labeling peptide mapping method
EP4412713A1 (en) 2021-10-05 2024-08-14 GlaxoSmithKline Intellectual Property Development Ltd Combination therapies for treating cancer
CN118475353A (en) 2021-12-17 2024-08-09 Viiv保健公司 Combination therapy for HIV infection and uses thereof
JP2025514374A (en) 2022-04-29 2025-05-02 ２３アンドミー・インコーポレイテッド Antigen-binding proteins
EP4577569A1 (en) 2022-08-25 2025-07-02 GlaxoSmithKline Intellectual Property Development Ltd Antigen binding proteins and uses thereof
TW202430564A (en) 2022-10-20 2024-08-01 英商葛蘭素史密斯克藍智慧財產權有限公司 Antigen binding proteins
CR20250219A (en) 2022-11-02 2025-09-18 Viiv Healthcare Uk No 5 Ltd Antigen binding proteins
AR134489A1 (en) 2023-11-27 2026-01-21 Glaxosmithkline Ip Dev Ltd ANTIGEN-BINDING PROTEINS
TW202544037A (en) 2023-12-11 2025-11-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 Antigen binding proteins
WO2025229018A1 (en) 2024-04-30 2025-11-06 VIIV Healthcare UK (No.5) Limited Neutralizing antibody constructs against hiv
WO2025229019A1 (en) 2024-04-30 2025-11-06 VIIV Healthcare UK (No.5) Limited Neutralizing antibody constructs against hiv
WO2025242652A1 (en) 2024-05-23 2025-11-27 Glaxosmithkline Intellectual Property Development Limited Pregnancy associated plasma protein-a (pappa) binding proteins
US20260008843A1 (en) 2024-06-21 2026-01-08 Glaxosmithkline Intellectual Property Development Limited Multispecific antigen binding proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
US6046310A (en) * 1996-03-13 2000-04-04 Protein Design Labs., Inc. FAS ligand fusion proteins and their uses

Also Published As

Publication number Publication date
JP2002505086A (en) 2002-02-19
HUP0100813A2 (en) 2001-06-28
CZ20003099A3 (en) 2002-04-17
AU2784299A (en) 1999-09-15
BR9908226A (en) 2000-10-24
EP1060194A1 (en) 2000-12-20
HK1036286A1 (en) 2001-12-28
WO1999043713A1 (en) 1999-09-02
AU758240B2 (en) 2003-03-20
NO20004218D0 (en) 2000-08-23
CN1291995A (en) 2001-04-18
PL199659B1 (en) 2008-10-31
HUP0100813A3 (en) 2003-08-28
PL342497A1 (en) 2001-06-04
CN1204147C (en) 2005-06-01
CA2320403A1 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
NO20004218D0 (en) Increasing the circulating half-life of an antibody-based fusion protein
FI971479L (en) Fused pyrrolocarbazoles
TR199501568A2 (en) Pioneers of Tasiki.
CY2008013I1 (en) ARYL FUSED AZAPOLYCYCLIC COMPOUNDS
FR2770110B1 (en) CASE, OF THE MAKEUP CASE TYPE
CY2007012I1 (en) ANTI-VEGF ANTIBODIES
DE69530137D1 (en) Tapered fusion cage
NO20000300D0 (en) Hydrogenolysis of glycerol
NO2010022I1 (en) denosumab
FR2717769B1 (en) CV joint.
ID29065A (en) TRANSFERAGE PROTEIN FARNESIL OBSTACLES
BR9704567A (en) Elements of fusion systems
DE69531578D1 (en) connection capillary
DK0917879T3 (en) Improved protein stabilization method
MX224819B (en) COSMETIC EMPLOYMENT OF DERIVATIVES OF BIS (RESORCINIL) TRIACINA.
DE69710440D1 (en) joint arrangement
NO980566D0 (en) Allergen-XCD32 fusion proteins
BR9901328B1 (en) fuser member.
NO993584L (en) Bias type connection
ID25903A (en) OFTALMIK LENS HOLOGRAFIK
FI974244A0 (en) Foerfarande Foer kompressering av en bild
ITTO940248A0 (en) HYDRODYNAMIC JOINT.
DK0862197T3 (en) Fused Connection
DE59812914D1 (en) TIGHT FIT CONNECTION
NO982014L (en) Procedure for calculating the duration of connections

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application